Search research articles
Contact Us
Filters
Showing results (41-50 of 43) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 43 results.
The Lancet. Oncology
|
May 17, 2014
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial
Vanesa Gregorc, Silvia Novello, Chiara Lazzari, et al.
Cell Reports. Medicine
|
February 25, 2024
SEPN1-related myopathy depends on the oxidoreductase ERO1A and is druggable with the chemical chaperone TUDCA
Serena Germani, Andrew Tri Van Ho, Alessandro Cherubini, et al.
Cerebral Cortex (New York, N.Y. : 1991)
|
March 24, 2016
eEF2K/eEF2 Pathway Controls the Excitation/Inhibition Balance and Susceptibility to Epileptic Seizures
Christopher Heise, Elham Taha, Luca Murru, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 43) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 43 results.
The Lancet. Oncology
|
May 17, 2014
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial
Vanesa Gregorc, Silvia Novello, Chiara Lazzari, et al.
Cell Reports. Medicine
|
February 25, 2024
SEPN1-related myopathy depends on the oxidoreductase ERO1A and is druggable with the chemical chaperone TUDCA
Serena Germani, Andrew Tri Van Ho, Alessandro Cherubini, et al.
Cerebral Cortex (New York, N.Y. : 1991)
|
March 24, 2016
eEF2K/eEF2 Pathway Controls the Excitation/Inhibition Balance and Susceptibility to Epileptic Seizures
Christopher Heise, Elham Taha, Luca Murru, et al.
Page
of 5